Introduction Immune checkpoint inhibitors like Pembrolizumab have transformed oncology care across multiple solid tumours. Recently, a subcutaneous (SC) formulation has been introduced using hyaluronidase technology, promising faster administration, improved patient convenience, and reduced infusion burden.
Introduction
Immune checkpoint inhibitors like Pembrolizumab have transformed oncology care across multiple solid tumours. Recently, a subcutaneous (SC) formulation has been introduced using hyaluronidase technology, promising faster administration, improved patient convenience, and reduced infusion burden. This transition from intravenous (IV) to SC delivery is being positioned as a patient-centred innovation in cancer care.
Problem Statement
Despite enthusiasm, the key question remains: does SC pembrolizumab truly improve patient outcomes or system efficiency—or is it primarily a commercial strategy? Several concerns emerge:
Approval is based on pharmacokinetic non-inferiority, not clinical superiority
No meaningful improvement in survival, efficacy, or safety
Timing coincides with patent expiry, suggesting “patent hopping”
Fixed high-dose SC regimens limit:
Dose optimization
Cost-saving strategies (e.g., weight-based dosing, vial sharing)
Real-world “convenience” may be overestimated due to:
Pre-injection logistics (drug warming, scheduling)
Combination therapy with chemotherapy (no time saving)
Increased system complexity (home administration challenges)
Core issue: Is convenience being used to justify increased healthcare costs without added value?
Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...
Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...
Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond...
Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...
Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...
Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.